$BDRL
BLONDER TONGUE LABORATORIES INC Stock $bdrl

$bdrl Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417027059 Filed on May 15, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q4
Revenue	$6.160M	$5.973M	$5.450M
YoY Change	8.41%	0.5%	4.61%
Cost Of Revenue	$4.040M	$3.572M	$3.680M
YoY Change	26.05%	-4.36%	-22.53%
Gross Profit	$2.130M	$2.401M	$1.770M
YoY Change	-14.01%	8.74%	276.6%
Gross Profit Margin	34.58%	40.2%	32.48%
Selling, General & Admin	$1.620M	$1.607M	$1.420M
YoY Change	4.65%	-6.3%	-18.86%
% of Gross Profit	76.06%	66.93%	80.23%
Research & Development	$644.0K	$628.0K	$640.0K
YoY Change	-7.2%	-9.38%	-12.33%
% of Gross Profit	30.23%	26.16%	36.16%
Depreciation & Amortization	$170.0K	$86.00K	$220.0K
YoY Change	-34.62%	-28.33%	-29.03%
% of Gross Profit	7.98%	3.58%	12.43%
Operating Expenses	$2.263M	$2.235M	$2.060M
YoY Change	0.94%	-7.18%	-16.94%
Operating Profit	-$138.0K	$166.0K	-$290.0K
YoY Change	-158.72%	-183.0%	-85.57%
Interest Expense	$93.00K	$280.0K	-$20.00K
YoY Change	-203.33%	218.18%	-75.0%
% of Operating Profit		168.67%
Other Income/Expense, Net
YoY Change
Pretax Income	-$231.0K	-$256.0K	-$310.0K
YoY Change	-416.44%	-11.11%	-85.17%
Income Tax	$0.00	$0.00	$30.00K
% Of Pretax Income
Net Earnings	-$231.0K	-$256.0K	-$340.0K
YoY Change	-416.44%	-11.11%	-84.11%
Net Earnings / Revenue	-3.75%	-4.29%	-6.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.03	-$0.03	-$0.04
COMMON SHARES
Basic Shares Outstanding	8.122M shares	8.122M shares	8.098M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$360.0K	$540.0K	$470.0K
YoY Change	16.13%	5.88%	4600.0%
Cash & Equivalents	$361.0K		$468.0K
Short-Term Investments
Other Short-Term Assets	$260.0K	$440.0K	$280.0K
YoY Change	-16.13%	0.0%	0.0%
Inventory	$5.305M	$5.100M	$5.064M
Prepaid Expenses
Receivables	$2.344M	$2.350M	$2.273M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.274M	$8.431M	$8.080M
YoY Change	-3.11%	-12.87%	-2.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.160M	$3.211M	$3.279M
YoY Change	-6.78%	-8.34%	-9.44%
Goodwill	$493.0K	$493.0K	$493.0K
YoY Change		0.0%	0.0%
Intangibles			$117.0K
YoY Change			-74.45%
Long-Term Investments
YoY Change
Other Assets	$380.0K	$416.0K	$428.0K
YoY Change	-67.8%	255.56%	265.81%
Total Long-Term Assets	$6.440M	$6.667M	$6.920M
YoY Change	-8.28%	-11.38%	-12.59%
TOTAL ASSETS
Total Short-Term Assets	$8.274M	$8.431M	$8.080M
Total Long-Term Assets	$6.440M	$6.667M	$6.920M
Total Assets	$14.71M	$15.10M	$15.00M
YoY Change	-5.44%	-12.22%	-7.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.240M	$1.350M	$1.390M
YoY Change	42.53%	-32.47%	0.22%
Accrued Expenses	$720.0K	$720.0K	$600.0K
YoY Change	-5.26%	-30.1%	-37.5%
Deferred Revenue
YoY Change
Short-Term Debt	$1.970M	$2.050M	$2.120M
YoY Change	-11.66%	-28.07%	-20.3%
Long-Term Debt Due	$246.0K	$246.0K	$228.0K
YoY Change	-92.95%	-93.07%	-93.67%
Total Short-Term Liabilities	$4.176M	$4.357M	$4.616M
YoY Change	-45.12%	-54.67%	-46.46%
LONG-TERM LIABILITIES
Long-Term Debt	$3.211M	$3.273M	$3.335M
YoY Change	817.43%	109000.0%	33250.0%
Other Long-Term Liabilities			$0.00
YoY Change
Total Long-Term Liabilities	$3.211M	$3.273M	$3.335M
YoY Change	817.43%	109000.0%	33250.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.176M	$4.357M	$4.616M
Total Long-Term Liabilities	$3.211M	$3.273M	$3.335M
Total Liabilities	$8.113M	$8.339M	$8.466M
YoY Change	0.41%	-13.27%	-1.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.67M	-$17.44M	-$17.18M
YoY Change		39.64%	40.83%
Common Stock	$26.69M	$26.62M	$26.14M
YoY Change		0.78%	-0.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.149M	$1.149M	$1.149M
YoY Change		-79.61%	-79.61%
Treasury Stock Shares	342.0 shares	342.0K shares	342.0 shares
Shareholders Equity	$6.601M	$6.759M	$6.534M
YoY Change
Total Liabilities & Shareholders Equity	$14.71M	$15.10M	$15.00M
YoY Change	-5.44%	-12.22%	-7.58%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q4
OPERATING ACTIVITIES
Net Income	-$231.0K	-$256.0K	-$340.0K
YoY Change	-416.44%	-11.11%	-84.11%
Depreciation, Depletion And Amortization	$170.0K	$86.00K	$220.0K
YoY Change	-34.62%	-28.33%	-29.03%
Cash From Operating Activities	-$20.00K	$240.0K	$10.00K
YoY Change	-104.08%	-1300.0%	-102.27%
INVESTING ACTIVITIES
Capital Expenditures	$30.00K	$18.00K	-$30.00K
YoY Change		800.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$30.00K	-$40.00K	$30.00K
YoY Change		300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$44.00K
YoY Change		-30.16%
Cash From Financing Activities	-130.0K	-120.0K	210.0K
YoY Change	-81.16%	-122.64%	31.25%
NET CHANGE
Cash From Operating Activities	-20.00K	240.0K	10.00K
Cash From Investing Activities	-30.00K	-40.00K	30.00K
Cash From Financing Activities	-130.0K	-120.0K	210.0K
Net Change In Cash	-180.0K	80.00K	250.0K
YoY Change	-10.0%	-84.0%	-189.29%
FREE CASH FLOW
Cash From Operating Activities	-$20.00K	$240.0K	$10.00K
Capital Expenditures	$30.00K	$18.00K	-$30.00K
Free Cash Flow	-$50.00K	$222.0K	$40.00K
YoY Change	-110.2%	-1109.09%	-109.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3211000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	319000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	197000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4357000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4616000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3273000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3335000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	139000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	139000	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	26613000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	26132000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17435000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17179000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1278000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1278000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1149000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	117000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1569000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1612000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3279000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	8080000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	8431000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	275000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	436000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	468000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1390000	USD
CY2017Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	295000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	320000	USD
CY2017Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	101000	USD
CY2016Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	101000	USD
CY2017Q1	us-gaap	Selling Expense SellingExpense	679000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6765000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8122000	shares
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-256000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-288000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-256000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-288000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5973000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5943000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3572000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3735000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	2401000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	2208000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	493000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	493000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	416000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	428000	USD
CY2017Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2046000	USD
CY2016Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2120000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	246000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	228000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1350000	USD
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1149000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	6759000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6534000	USD
CY2017Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	894000	USD
CY2016Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	991000	USD
CY2017Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	260000	USD
CY2017Q1	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	570000	USD
CY2016Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	376000	USD
CY2016Q1	us-gaap	Selling Expense SellingExpense	652000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	928000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1063000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	628000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	693000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	166000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-200000	USD
CY2017Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-142000	USD
CY2016Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2017Q1	us-gaap	Depreciation Depreciation	86000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	120000	USD
CY2017Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	101000	USD
CY2016Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	144000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	79000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	45000	USD
CY2017Q1	us-gaap	Inventory Write Down InventoryWriteDown	-48000	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	48000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	81000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	719000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-111000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-109000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	161000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	161000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-12000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	57000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	679000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	236000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-43000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	44000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	63000	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-74000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	190000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-118000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	527000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	75000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	504000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	513000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	57000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	76000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4000	USD
CY2017Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000	USD
CY2017Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2016Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	400000	USD
CY2017Q1	us-gaap	Interest Expense Other InterestExpenseOther	194000	USD
CY2016Q1	us-gaap	Interest Expense Other InterestExpenseOther	6000	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1467000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1924000	shares
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3607000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4001000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1985000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1860000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3221000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4143000	USD
CY2017Q1	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	2821000	USD
CY2016Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	3949000	USD
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	BLONDER TONGUE LABORATORIES INC
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001000683
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Trading Symbol TradingSymbol	BDR
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8121835	shares
CY2017Q1	us-gaap	Assets Assets	15098000	USD
CY2016Q4	us-gaap	Assets Assets	15000000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	8339000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	8466000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15098000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15000000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	180000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	180000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8465000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8465000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8122000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8122000	shares
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	342000	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	342000	shares
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	2235000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	2408000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	280000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	88000	USD
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"> (a)          Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include stock compensation and reserves related to accounts receivable, inventory and deferred tax assets. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> (b)          Derivative Financial Instruments</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“<b>FASB</b>”) Accounting Standards Codification (<b>“ASC</b>”). The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option at its fair value as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Black-Scholes Model (which approximates the Binomial Lattice Model) was used to estimate the fair value of the conversion options that is classified as a derivative liability on the condensed consolidated balance sheets (See Note 6). The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the conversion options.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion options are recorded as a discount to the host instrument and are amortized as interest expense over the life of the underlying instrument.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Inventory Gross InventoryGross	10004000	USD
CY2016Q4	bdr	Inventory Value Before Reserves InventoryValueBeforeReserves	4940000	USD
CY2017Q1	bdr	Percentage Of Fifo Inventory Non Current For Finished Goods PercentageOfFifoInventoryNonCurrentForFinishedGoods	0.68	pure
CY2017Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	402000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	177000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	6000	USD

Files In Submission

Name	View Source	Status
0001144204-17-027059-index-headers.html	Edgar Link	pending
0001144204-17-027059-index.html	Edgar Link	pending
0001144204-17-027059.txt	Edgar Link	pending
0001144204-17-027059-xbrl.zip	Edgar Link	pending
bdr-20170331.xml	Edgar Link	completed
bdr-20170331.xsd	Edgar Link	pending
bdr-20170331_cal.xml	Edgar Link	unprocessable
bdr-20170331_def.xml	Edgar Link	unprocessable
bdr-20170331_lab.xml	Edgar Link	unprocessable
bdr-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v465560_10q.htm	Edgar Link	pending
v465560_ex31-1.htm	Edgar Link	pending
v465560_ex31-2.htm	Edgar Link	pending
v465560_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDRL
BLONDER TONGUE LABORATORIES INC Stock $bdrl

2017 Q2 Form 10-Q Financial Statement

#000114420417027059 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDRL BLONDER TONGUE LABORATORIES INC Stock $bdrl

2017 Q2 Form 10-Q Financial Statement

#000114420417027059 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDRL
BLONDER TONGUE LABORATORIES INC Stock $bdrl